TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06674811

Intervention type: OTHER
Intervention: Patient Report Outcomes
Description: To obtain patient-reported outcomes (PROs), questionnaires will be administered at time of enrollment, in the two weeks prior to surgery if applicable, and at 1, 2, 4, 8, 12, 16, 20, 24, 34, 44, and 54 weeks postoperatively. Questionnaires can be completed electronically, over the telephone or in person. The PedsQL Cancer Module and Patient Health Questionnaire depression scale (PHQ-9) will be utilized for questionnaires.

Intervention type: OTHER
Intervention: Patient Report Outcomes
Description: To obtain patient-reported outcomes (PROs), questionnaires will be administered at time of enrollment, in the two weeks prior to surgery if applicable, and at 1, 2, 4, 8, 12, 16, 20, 24, 34, 44, and 54 weeks postoperatively. Questionnaires can be completed electronically, over the telephone or in person. The PedsQL Cancer Module and Patient Health Questionnaire depression scale (PHQ-9) will be utilized for questionnaires.

Intervention type: OTHER
Intervention: Blood Draw
Description: When patients are having blood drawn as part of their regular care, extra blood may be drawn for this study. Participants may opt out of this. Blood draws will occur preoperatively and at intervals postoperatively for proteomic, metabolomic, and exposomic testing.
Study: NCT06674811

Intervention type: OTHER
Intervention: Clinical Data Review
Description: Clinical data will be collected and stored in a database by study staff. This includes patient demographics, diagnosis characteristics including staging and risk group, treatment characteristics, and outcomes including length of stay following surgical intervention, readmissions, surgical complications including surgical site infection, time off therapy/time to resumption of chemotherapy.
Study: NCT06367556

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotion and Symptom-Focused Engagement (EASE)
Description: EASE sessions are directed to provide relational support, affect regulation, and problem-solving related to cancer in the child, to changes in spousal, family, and other relationships, and to the burden of multiple individual and family responsibilities.
Study: NCT06609356

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Study Visit 1
Description: Hyperinsulinemic, euglycemic clamp and flow-mediated dilation (FMD) study. The study will randomize participants to first receive a five-hour intravenous insulin infusion to achieve normal plasma insulin concentrations (Eu-Ins) or higher plasma insulin concentrations (Hi-Ins)
Study: NCT06607185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY4066434.
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY4066434.
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: Administered intravenously.
Study: NCT06609356

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Study Visit 1
Description: Hyperinsulinemic, euglycemic clamp and flow-mediated dilation (FMD) study. The study will randomize participants to first receive a five-hour intravenous insulin infusion to achieve normal plasma insulin concentrations (Eu-Ins) or higher plasma insulin concentrations (Hi-Ins)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: * T1DM participants in the Hi-Ins study will receive an oral placebo. During the Eu-Ins study they will receive an SGLT2i.~* CGK-MODY participants and healthy volunteers will receive placebo in both studies.
Study: NCT06607185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5Fluorouracil
Description: Administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered intravenously.
Study: NCT06605599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-932
Description: Oral Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-932
Description: Oral Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-932
Description: Oral Capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for ABBV-932
Description: Oral Capsule
Study: NCT05361980

Intervention type: DEVICE
Intervention: Pediatric orthopaedic implant
Description: Patient receives a pediatric orthopaedic implant as a part of standard clinical care.
Study: NCT06609356

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: * T1DM participants in the Hi-Ins study will receive an oral placebo. During the Eu-Ins study they will receive an SGLT2i.~* CGK-MODY participants and healthy volunteers will receive placebo in both studies.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Study Visit 2
Description: Hyperinsulinemic, euglycemic clamp and flow-mediated dilation (FMD) study. Insulin levels infused during the five-hour insulin infusion will be opposite of the first visit.
Study: NCT06600581

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMM01-STEM
Description: IMM01-STEM is an allogeneic cell-free secretome product derived from partially differentiated human stem cells derived from a pluripotent embryonic stem cell line that was established from a single donor IVF discarded blastocyst. The cells are cultivated in bioreactors and the product of their secretion is collected, purified and concentrated to a standardized formulation. The secretome contains a mixture of molecules related to immunomodulation, growth, and extracellular matrix remodeling. This intervention is given 2mL twice a week.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMM01-STEM
Description: IMM01-STEM is an allogeneic cell-free secretome product derived from partially differentiated human stem cells derived from a pluripotent embryonic stem cell line that was established from a single donor IVF discarded blastocyst. The cells are cultivated in bioreactors and the product of their secretion is collected, purified and concentrated to a standardized formulation. The secretome contains a mixture of molecules related to immunomodulation, growth, and extracellular matrix remodeling. This intervention is given 2mL twice a week.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline. This intervention is given 2mL twice a week.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMM01-STEM alternating with placebo (saline)
Description: This intervention consists of IMM01-STEM given once a week and placebo given one a week. IMM01-STEM is an allogeneic cell-free secretome product derived from partially differentiated human stem cells derived from a pluripotent embryonic stem cell line that was established from a single donor IVF discarded blastocyst. The cells are cultivated in bioreactors and the product of their secretion is collected, purified and concentrated to a standardized formulation. The secretome contains a mixture of molecules related to immunomodulation, growth, and extracellular matrix remodeling.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMM01-STEM alternating with placebo (saline)
Description: This intervention consists of IMM01-STEM given once a week and placebo given one a week. IMM01-STEM is an allogeneic cell-free secretome product derived from partially differentiated human stem cells derived from a pluripotent embryonic stem cell line that was established from a single donor IVF discarded blastocyst. The cells are cultivated in bioreactors and the product of their secretion is collected, purified and concentrated to a standardized formulation. The secretome contains a mixture of molecules related to immunomodulation, growth, and extracellular matrix remodeling.
Study: NCT06447519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ca(OH)2 as intracanal medicament
Description: Ca(OH2 will be used as intracanal medicament for the disinfection of the root canal between appointmnents
Study: NCT05977751

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FemBloc
Description: Treatment for women who desire non-surgical permanent birth control by occlusion of the fallopian tubes.
Study: NCT06676904

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Higher Platelet Transfusion Threshold
Description: Infants randomized to this arm will be monitored for a platelet transfusion threshold of 50 x 10\^9/L up to 7 days of life, and then for a platelet transfusion threshold of 35 x 10\^9/L at 7 or more days of life. Infants will remain on this protocol-driven threshold through 40 0/7 weeks postmenstrual age. The platelet dose will be 10 ml/kg administered over 60-120 minutes.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Lower Platelet Transfusion Threshold
Description: Infants randomized to this arm will be monitored for a platelet transfusion threshold of 25 x 10\^9/L up to 7 days of life, and then for a platelet transfusion threshold of 20 x 10\^9/L at 7 or more days of life. Infants will remain on this protocol-driven threshold through 40 0/7 weeks postmenstrual age. The platelet dose will be 10 ml/kg administered over 60-120 minutes.
Study: NCT06676267

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Description: The laparoscopic surgery system is applied to gynecology and 5G remote surgical treatment.
Study: NCT05003583

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speaking after viewing pictures with negative and neutral valence
Description: Speaking Condition 1: 10 age-appropriate pictures from the International Affective Picture System (IAPS; Lang, Bradley \& Cuthbert, 2005) will be shown to participants. These pictures are classified as high arousal, negative valence stimuli. Participants will be asked to repeat a simple phrase between picture presentations.~Speaking Condition 2: A blank screen will be shown to participants in place of pictures. This condition is classified as low arousal, neutral valence. Participants will be asked to repeat a simple phrase between blank screen picture presentations.
Study: NCT06676033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epcoritamab
Description: Samples from subjects receiving epcoritamab on another clinical trial GCT3013-03 will be collected.
Study: NCT06676592

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Preoperative imaging
Description: Preoperative imaging will be performed as part of the standard of care. Imaging data from US, CT, MRI, and/or PET performed for routine care will be used for this study.
Study: NCT06609356

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Study Visit 2
Description: Hyperinsulinemic, euglycemic clamp and flow-mediated dilation (FMD) study. Insulin levels infused during the five-hour insulin infusion will be opposite of the first visit.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor
Description: Concurrent with starting the five-hour infusion, T1DM participants in the Eu-Ins study will receive an SGLT2i dose (empagliflozin 25 mg).
Study: NCT06659952

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIV-positive heart transplant
Description: Receipt of heart from HIV-positive deceased donor only as part of this study
Study: NCT06664151

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone Trivalent
Description: Inactivated influenza vaccine, 0.5mL single-dose, pre-filled syringe, via intratumoral (into a tumor) injection per protocol.
Study: NCT06609148

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: De Simone formulation probiotic
Description: Subjects will be given De Simone formulation probiotic 900 billion CFU, 3 times per day for 21-24 days

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be given a placebo for 21-24 days
Study: NCT06676592

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 3D framework
Description: 3D images of surface landmarks will be acquired by use of US and the Scaniverse app before surgery, in conjunction with the participant's standard-of-care US or US-guided biopsy procedure
Study: NCT05097885

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sub Acute Whole Body Vibration Training
Description: Participants will be given a personal vibration plate to take home with them for training which will last for 12 weeks. For the first four weeks, participants will be asked to complete 10 minutes of WBV per day (1 minute on and up to 1 minute of rest), at least 3-4 days per week. At least 24 hours will be recommended in between sessions during weeks 1-4. Beginning at week 5, participants will be asked to increase WBV time to up to 14 minutes and/or reduce the duration of rest. Beginning at week 9, participants will be asked to increase WBV time to up to 20 minutes and/or reduce the duration of rest.
Study: NCT05117008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin
Description: Belantamab mafodotin will be administered IV over approximately 30 minutes at the recommended dose of 2.5 mg/kg IV over 30 minutes on day 1 of every eight-week (+/- three days) cycle for a maximum of 12 cycles. Maintenance therapy with belantamab mafodotin will continue until progressive disease (PD), death, unacceptable toxicity, withdrawal of consent or end of study (maximum of 12 cycles), whichever occurs first.
Study: NCT04953104

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diagnostic Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study: NCT05860504

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac magnetic resonance imaging
Description: Sub-group of patients with left ventricular systolic dysfunction will be examined with cMRI

Intervention type: DIAGNOSTIC_TEST
Intervention: Coronary CT
Description: Sub-group of patients with left ventricular systolic dysfunction will be examined with CCT
Study: NCT04953104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relatlimab
Description: Given IV
Study: NCT05944081

Intervention type: DEVICE
Intervention: ArcadiusXP L® Interbody Fusion System
Description: The ArcadiusXP L® Interbody Fusion System is a stand-alone device intended to be used with four bone screws if no supplement fixation is used to stabilize the lumbar spine through an anterior approach. Levels of anterior lumbar interbody fusion for the indications listed in the instructions for use are from L2-S1.
Study: NCT06351137

Intervention type: OTHER
Group type: OTHER
Intervention: Intravenous administration
Description: Analgesia is administered intravenously.

Intervention type: OTHER
Group type: OTHER
Intervention: Intravenous administration
Description: Analgesia is administered intravenously.

Intervention type: OTHER
Group type: OTHER
Intervention: Intranasal administration
Description: Analgesia is administered intranasally using an atomizer.

Intervention type: OTHER
Group type: OTHER
Intervention: Intranasal administration
Description: Analgesia is administered intranasally using an atomizer.
Study: NCT04822350

Intervention type: DRUG
Intervention: Avelumab
Description: As provided in real world practice
Study: NCT06308653

Intervention type: DRUG
Group type: OTHER
Intervention: Psilocybin 25 mg
Description: The Psilocybin used in this study is synthetically manufactured in a laboratory and meets quality specifications suitable for human research use. The active drug is encapsulated within a hydroxypropyl methylcellulose (HPMC) capsule and contains 25 mg of Psilocybin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin 25 mg
Description: The Psilocybin used in this study is synthetically manufactured in a laboratory and meets quality specifications suitable for human research use. The active drug is encapsulated within a hydroxypropyl methylcellulose (HPMC) capsule and contains 25 mg of Psilocybin.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inactive Placebo
Description: The inactive placebo is encapsulated within a hydroxypropyl methylcellulose (HPMC) capsule and contains 25 mg of Microcrystalline Cellulose (MCC). The MCC is synthetically manufactured in a laboratory and meets quality specifications suitable for human research use.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Psilocybin 5 mg
Description: The Psilocybin used in this study is synthetically manufactured in a laboratory and meets quality specifications suitable for human research use. The active comparator is encapsulated within a hydroxypropyl methylcellulose (HPMC) capsule and contains 5 mg of Psilocybin.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Psychosocial Support
Description: Psychosocial Support, including psychoeducation, begins after the Double-blind Period and continues throughout the 1-year Follow-up Period in order to enhance participant safety and maximize retention for the entire trial duration.
Study: NCT06617143

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mindfulness-based cognitive therapy
Description: In this study, it is planned to apply MBCT to asthmatic inpatients in the patient room in groups of 2 or 3. This application is planned to continue for one hour.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: routine treatment and care
Description: routine treatment and care
Study: NCT06616142

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: [18F]CETO tracer
Description: PET/CT with para-chloro-2-\[18F\]fluoroethyl-etomidate (\[18F\]CETO) has a high specificity for the steroidogenic enzymes CYP11B1 and CYP11B2, present in the adrenal cortex, and has more favourable tracer characteristics compared to \[11C\]metomidate. Results obtained with this novel tracer seem promising, but its potential value in the subtyping of PA needs to be further established.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: [18F]CETO tracer
Description: PET/CT with para-chloro-2-\[18F\]fluoroethyl-etomidate (\[18F\]CETO) has a high specificity for the steroidogenic enzymes CYP11B1 and CYP11B2, present in the adrenal cortex, and has more favourable tracer characteristics compared to \[11C\]metomidate. Results obtained with this novel tracer seem promising, but its potential value in the subtyping of PA needs to be further established.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone oral
Description: Pre-treatment of dexamethasone prior to 18F CETO PET/CT scan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone oral
Description: Pre-treatment of dexamethasone prior to 18F CETO PET/CT scan
Study: NCT05758181

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Apical Undermining
Description: The skin at the tip of the wound will be freed to reduce tension.
Study: NCT06616142

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adrenal vein sampling
Description: Adrenl vein sampling

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adrenal vein sampling
Description: Adrenl vein sampling
Study: NCT06171698

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Research Prototype Monitor
Description: Continuous vital sign is collected via a research prototype monitor
Study: NCT06479174

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHAMPS-TR
Description: Persons with stroke ( n=20) and at least 1 targeted family member (TFM) (n=20) will engage with the CHAMPS-TR protocol which involves 10 virtual intervention sessions (bi-weekly for 5 weeks) with key elements including metacognitive problem-solving training (i.e., goal setting, guided discovery, strategy development) and vascular risk reduction coaching building on existing American Heart Association (AHA) LE8 content. Probands that are eligible for RS-tDCS (n=10) will receive 5x weekly (weeks 2-5) RS-tDCS applied to the left dorsolateral prefrontal cortex (DLPFC).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHAMPS-TR
Description: Persons with stroke ( n=20) and at least 1 targeted family member (TFM) (n=20) will engage with the CHAMPS-TR protocol which involves 10 virtual intervention sessions (bi-weekly for 5 weeks) with key elements including metacognitive problem-solving training (i.e., goal setting, guided discovery, strategy development) and vascular risk reduction coaching building on existing American Heart Association (AHA) LE8 content. Probands that are eligible for RS-tDCS (n=10) will receive 5x weekly (weeks 2-5) RS-tDCS applied to the left dorsolateral prefrontal cortex (DLPFC).
Study: NCT06671002

Intervention type: DRUG
Group type: OTHER
Intervention: NSAID
Description: Once randomized to this group the surgical team will elect to prescribe 1 of the following treatment options for post-discharge pain:~* Ibuprofen 10 milligrams(mg)/kilogram (kg) (maximum 600mg) by mouth every 6 hours around the clock for 2 days, then as needed for pain thereafter (40 doses)~* Celecoxib 6mg/kg (maximum 400mg) by mouth once then 3 mg/kg (maximum 200mg) every 12 hours around the clock for 2 days, then as needed for pain thereafter (40 doses)

Intervention type: DRUG
Group type: OTHER
Intervention: Opioid
Description: Once randomized to this group the surgical team will elect to prescribe for 1 of the following treatment options to be given post procedure for post-discharge pain:~* Oxycodone 0.1 mg/kg (maximum 5 mg) by mouth every 4 to 6 hours as needed for pain, number 10 doses.~* Hydromorphone 0.04 mg/kg (maximum mg) by mouth 4 to 6 hours as needed, number 10 doses

Intervention type: DRUG
Group type: OTHER
Intervention: Acetaminophen
Description: Participants will receive 15mg/kg up to 1000mg by mouth every 6 hours around the clock for the first 2 days after discharge from surgery then as needed thereafter (40 doses)

Intervention type: DRUG
Group type: OTHER
Intervention: Acetaminophen
Description: Participants will receive 15mg/kg up to 1000mg by mouth every 6 hours around the clock for the first 2 days after discharge from surgery then as needed thereafter (40 doses)

Intervention type: DRUG
Group type: OTHER
Intervention: Ibuprofen
Description: Ibuprofen 10mg/kg (maximum 600 mg) by mouth every 6 hours around the clock for 2 days after discharge from surgery then as needed thereafter (40 doses)
Study: NCT06672510

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ATC
Description: The ATC System is designed to mechanically remove emboli and restore blood flow through the pulmonary arteries in patients experiencing acute P